Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.82 |
| ▸ | FNTB | P49356 | 8/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11955246 | 1.00 | FNTA (0.82) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL1683558 | 0.91 | FNTA (0.79) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL13928075 | 0.91 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL1682772 | 0.91 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| Hydrochloric Acid SCHEMBL6435591 | 0.90 | FNTA (0.98) | FNTAFNTBCYP3A4 | |
| SCHEMBL13573626 | 0.90 | FNTA (0.66) | FNTAFNTBCYP3A4 | |
| SCHEMBL13573672 | 0.89 | CYP3A4 (0.70) | FNTAFNTBCYP3A4 | |
| SCHEMBL11947166 | 0.89 | FNTA (0.82) | FNTAFNTBCYP3A4 | |
| SCHEMBL5734500 | 0.89 | FNTA (0.87) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL5654543 | 0.89 | FNTA (0.96) | FNTAFNTBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253183-B2 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-1162201-B1 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-29 | — | — | EP | disclosed |
| US-20040198771-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | END DAVID WILLIAM (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040157882-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | END DAVID WILLIAM (US) | 2004-08-12 | — | — | US | disclosed |
| US-6743805-B2 | TREATING VASCULAR PROLIFERATIVE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-01 | — | — | US | disclosed |
| US-6734194-B2 | TO PREVENT OR TREAT VASCULAR PROLIFERATIVE DISORDERS SUCH AS ATHEROSCLEROSIS AND RESTENOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-11 | — | — | US | disclosed |
| US-20030229118-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | END DAVID WILLIAM (US) | 2003-12-11 | — | — | US | disclosed |
| US-6495564-B1 | SUCH AS 3-(6-((4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL)-1-METHYL-2-OXO-1,2-DIHYDRO-QUINOLIN-4-YL)-BENZALDEHYDE O-METHYL-OXIME; INHIBITING ABNORMAL CELL GROWTH | PFIZER INC. | 2002-12-17 | — | — | US | disclosed |
| EP-0988038-B1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA NV (BE) | 2002-08-14 | — | — | EP | disclosed |
| US-6420387-B1 | ANTITUMOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-16 | — | — | US | disclosed |
| US-20020091138-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | END DAVID WILLIAM (US) | 2002-07-11 | — | — | US | disclosed |
| EP-0865440-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-04-03 | — | — | EP | disclosed |
| EP-1162201-A9 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-03 | — | — | EP | disclosed |
| US-6365600-B1 | FOR THERAPY OF CONDITION ASSOCIATED WITH SMOOTH MUSCLE CELL PROLIFERATION IN A WARM-BLOODED ANIMAL WHICH COMPRISES ADMINISTERING IMIDAZOL-5-YL-METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. | 2002-04-02 | — | — | US | disclosed |
| EP-1162201-A2 | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-12-12 | — | — | EP | disclosed |
| US-6169096-B1 | FOR INHIBITING TUMOR GROWTH IN A MAMMAL | JANSSEN PHARMACAEUTIC N.V. (BE) | 2001-01-02 | — | — | US | disclosed |
| EP-0988038-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-29 | — | — | EP | disclosed |
| US-6037350-A | USEFUL AS ANTICANCER AGENTS FOR TUMORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-03-14 | — | — | US | disclosed |
| WO-1998055124-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229118-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | MYLK, ACTN1, ALK | FNTA 4747/4885FNTB 4394/4885CYP3A4 3172/4885 |
| US-20020091138-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | MYLK, ACTN1, ALK | FNTA 4747/4885FNTB 4394/4885CYP3A4 3183/4885 |
| US-20040198771-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | MYLK, ACTN1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FNTA 4764/4885FNTB 4470/4885CYP3A4 3129/4885 |
| US-20040157882-A1 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | MYLK, ACTN1, ALK | FNTA 4747/4885FNTB 4394/4885CYP3A4 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.